IRVINE, Calif.--(BUSINESS WIRE)---- $HIND--ReShape Lifesciences® (Nasdaq: RSLS) announced today that its shareholders have approved all of the proposals necessary to complete the previously announced merger with Vyome Therapeutics, which is expected to be effective for the commencement of trading on Friday, August 15, 2025. The shares of common stock of the combined company are expected to commence trading on The Nasdaq Capital Market under the name Vyome Holdings, Inc. and the trading symbol "HIND." “Vy
Related Questions
What is the anticipated impact of the merger on the stock price of RSLS and the new ticker HIND on the commencement date?
Will the combined company maintain or expand its current collaborations and licensing agreements?
What is the expected valuation of the combined company and how does it compare to current market caps?
How will the merger affect the company's cash runway and future financing needs?
What are the projected earnings and revenue synergies from combining ReShape Lifesciences and Vyome Therapeutics?
Will there be any dilution for existing RSLS shareholders post‑merger?
Are there any regulatory or FDA milestones that could influence the timeline or success of the combined entity?
How does the merger impact the competitive positioning of Vyome Holdings within the biotech sector?
What are the key risks associated with integrating the two companies' pipelines and R&D programs?
How will the merger affect the liquidity and float of the new shares on Nasdaq?